Skip to main content

Advertisement

SpringerLink
Log in

Cost-effectiveness analysis of extended adjuvant endocrine therapy in the treatment of post-menopausal women with hormone receptor positive breast cancer

  • Review
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Five years of Tamoxifen (Standard TAM) is a common treatment option for early-stage, hormone receptor positive (HR+) breast cancer (BC). Extending Standard TAM by 5 additional years (Extended TAM) can improve survival and BC recurrences. In postmenopausal women, the use of extended aromatase inhibitors (Extended AI) after Standard TAM is an alternative to Extended TAM. This study examines the cost-effectiveness (CE) of extending Standard TAM with Extended TAM vs. Extended AI in postmenopausal HR+ early-stage BC patients. Three treatments were assessed: (1) Standard TAM; (2) Extended TAM; (3) Extended AI through a Markov model using a Canadian health system perspective, lifetime time-horizon, quality adjusted life years (QALYs), and a 5 % discount rate for future costs and utilities. Incremental cost-effectiveness ratios (ICERs) were calculated, and the impact of parameter uncertainty was assessed through probabilistic sensitivity analyses (SA) using conventional CE thresholds. The estimated total per person costs in 2012 Canadian dollars [$1.00 CAD = $0.99 US 2012] were the least for Extended TAM ($8,623 CAD) and most for Extended AI ($9,432 CAD). Extended AI was the most effective regimen, while Standard TAM was the least. Extended AI was cost-effective at conventional thresholds vs. Extended TAM (ICER: $3,402 CAD/QALY) which was robust to the SA. This study suggests that Extended AI and Extended TAM result in improved QALYs and lower healthcare costs vs Standard TAM. Extended AI results in the greatest improvement in QALYs and is the most cost-effective treatment alternative despite its higher drug costs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Canadian Cancer Statistics (2013). www.cancer.ca. Accessed 7 Oct 2013

  2. Brenner H, Hakulinen T (2004) Are patients diagnosed with breast cancer before age 50 years ever cured? J Clin Oncol 22(3):432–438

    Article  PubMed  Google Scholar 

  3. Petrelli F et al (2013) Five or more years of adjuvant endocrine therapy in breast cancer: a meta-analysis of published randomized trials. Breast Cancer Res Treat 140:233–240

    Article  CAS  PubMed  Google Scholar 

  4. Goss P et al (2009) Aromatase inhibitors (AIs) versus not (Placebo/Observation) as late extended adjuvant therapy for postmenopausal women with early stage breast cancer (BC): overview of randomized Trials of AIs after ~5 years of Tamoxifen. Cancer Res 65(24, Suppl. 3):Abstract 4081

    Article  Google Scholar 

  5. Goss PE et al (2003) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349(19):1793–1802

    Article  CAS  PubMed  Google Scholar 

  6. Gray RG, Rea D, Handley K et al (2013) aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. J Clin Oncol 31((suppl)):abstr 5

    Google Scholar 

  7. Davies C, Pan H, Godwin J et al (2013) Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor positive breast cancer: ATLAS, a randomized trial. Lancet 381:805–816

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  8. Bliss JM, Kilburn LS et al (2012) Disease-related outcomes with long-term follow-up: an updated analysis of the Intergroup Exemestane Study. J Clin Oncol 30(7):709–717

    Article  CAS  PubMed  Google Scholar 

  9. Jakesz R, Greli R et al (2007) Extended adjuvant therapy with Anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. J Natl Cancer Inst 99:1845–1853

    Article  CAS  PubMed  Google Scholar 

  10. Delea TE, El-Onagari K, Karnon J, Sofrygin O (2008) Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective. Breast Cancer Res Treat 108:375–387

    Article  PubMed  Google Scholar 

  11. Fleurence RL, Hollenbeak CS (2007) Rates and probabilities in economic modelling. Pharmacoeconomics 25(1):3–6

    Article  PubMed  Google Scholar 

  12. Canadian Agency for Drugs and Technologies in Health (2006) HTA: guidelines for the economic evaluation of health technologies: Canada, 3rd edn. http://www.cadth.ca

  13. Briggs AH et al (2012) Model parameter estimation and uncertainty analysis A report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group–6. Med Decis Mak 32(5):722–732

    Article  Google Scholar 

  14. Doubilet P, Begg CB, Weinstein MC, Braun P, McNeil BJ (1985) Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach. Med Decis Mak 5(2):157–177

    Article  CAS  Google Scholar 

  15. Briggs AH (1999) A Bayesian approach to stochastic cost-effectiveness analysis. Health Econ 8:257–261

    Article  CAS  PubMed  Google Scholar 

  16. Skedgel C, Rayson D, Dewar R, Younis T (2007) Cost-utility of adjuvant hormone therapies for breast cancer in post-menopausal women: sequential tamoxifen-exemestane and upfront anastrozole. Breast Cancer Res Treat 101:325–333

    Article  CAS  PubMed  Google Scholar 

  17. Winer EP et al (2005) American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor–positive breast cancer: status report 2004. J Clin Oncol 23(3):619–629

    Article  CAS  PubMed  Google Scholar 

  18. Cuzick J et al (2010) Effect of anastrozole and tamoxifen as adjuvant treatment for early stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 11(12):1135–1141

    Article  CAS  PubMed  Google Scholar 

  19. Goss PE et al (2013) Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27—a randomized controlled phase III trial. J Clin Oncol 31(11):1398–1403

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  20. Lamond Nathan WT, Skedgel C, Rayson D, Lethbridge L, Younis T (2012) Cost-utility of the 21-gene recurrence score assay in node-negative and node-positive breast cancer. Breast Cancer Res Treat 133:1115–1123

    Article  CAS  PubMed  Google Scholar 

  21. Sorensen SV et al (2004) Patient-rated utilities in postmenopausal early breast cancer (EBC): a cross-country comparison. Value Health 7(6):641

    Article  Google Scholar 

  22. Locker GY et al (2007) Costeffectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC (‘Arimidex’, Tamoxifen Alone or in Combination) trial. Breast Cancer Res Treat 106(2):229–238

    Article  CAS  PubMed  Google Scholar 

  23. Fryback DG et al (1993) The beaver dam health outcomes study. Initial catalog of health state quality factors. Med Decis Mak 13:89–102

    Article  CAS  Google Scholar 

  24. Ingle JN, Suman VJ (2005) Aromatase inhibitors for therapy of advanced breast cancer. J Steroid Biochem Mol Biol 95(3):119

    Google Scholar 

  25. Tengs T et al (2000) One thousand health-related quality-of-life estimates. Med Care 38(6):583–637

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada

    Aysegul Erman

  2. Institute of Health Policy Management and Evaluation, University of Toronto, Toronto, ON, Canada

    Arlene Nugent & Peter C. Coyte

  3. Princess Margaret Hospital, Toronto, ON, Canada

    Eitan Amir

Authors
  1. Aysegul Erman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Arlene Nugent
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Eitan Amir
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Peter C. Coyte
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Arlene Nugent.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Erman, A., Nugent, A., Amir, E. et al. Cost-effectiveness analysis of extended adjuvant endocrine therapy in the treatment of post-menopausal women with hormone receptor positive breast cancer. Breast Cancer Res Treat 145, 267–279 (2014). https://doi.org/10.1007/s10549-014-2950-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-014-2950-6

Keywords

Search

Navigation